Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. Click here to find out why RVMD ...

Shares of Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) have received an average rating of “Buy” from the twelve research firms that are currently covering the stock ...

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) hit a new 52-week low during mid-day trading on Saturday . The stock traded as low as $30.94 and last traded at $31.32, with a volume of ...

Stifel analyst Benjamin Burnett lowered the firm’s price target on Revolution Medicines (RVMD) to $64 from $78 and keeps a Buy rating on the ...

REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS ...

In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other debt free mid cap stocks. Debt-free mid-cap stocks currently offer ...

Revolution Medicines, Inc. REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies ...

About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D ...

In trading on Tuesday, shares of Revolution Medicines Inc (Symbol: RVMD) entered into oversold territory, hitting an RSI reading of 28.1, after changing hands as low as $33.25 per share.

Following the live webcasts, replays will be available on the company's website for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is a late-stage clinical oncology company ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...